Abstract: Adamantane derivatives in which two (meth)acryloyloxyalkyl groups are bonded with an adamantane ring through ester groups, adamantane derivatives in which two adamantane rings are bonded through an alkylene group and two urethane bonds, which two adamantane rings each have a (meth)acryloyloxy group bonded thereto directly or through a coupling group, and adamantane derivatives each having a structure in which a group containing an adamantane ring hangs on the alkylene group of an alkylene glycol di(meth)acrylate. The compounds are useful as dental materials intermediates therefor, and as intermediates for optical materials such as lenses.

Abstract: The use of compounds of the formula and pharmaceutically acceptable salts thereof, alone or in combination for the treatment of transplant rejection, wherein the substituents are further defined in the application.

Abstract: Process for producing mono- and poly-carboxylic aromatic acids wherein an aromatic compound having at least one oxidizable substituent directly linked to the carbon atom of the corresponding aromatic nucleus is oxidized in the presence of a catalyst system in the liquid homogenous phase. The oxidation reaction is carried out in aqueous acetic acid, and the catalyst system consists of a combination of cobalt and zirconium organic salts. The oxidation reaction is carried out at an absolute pressure lower than 10 bar and at a temperature of 90-150° C.

Abstract: Amidomethyl esters, carbonylmercaptomethyl esters, keto-containing esters, amidomethyl thioesters, amidomethyl amides, and methylene dithioesters are disclosed. The novel compounds have two carbonyl groups connected by a linking moiety having an oxygen, sulfur or nitrogen attached to a methylene group, to which is further attached a sulfur, nitrogen or CH2 group. Methods of treating illnesses and conditions, such as cancer, hemological disorders, inherited metabolic disorders and others, using these compounds are also disclosed.

Abstract: Disclosed are novel tert-butyl 4,4-bis(4′-hydroxyphenyl)pentanoate derivatives represented by the following general formula (I); wherein R1 represents a protective group which can be readily eliminated under an acidic condition, and R2 represents a hydrogen atom, a lower alkyl group or a lower alkoxy group: and high energy radiation-responsive positive resist materials using said novel derivatives as dissolution inhibitors.

Abstract: Compounds of the formula are provided wherein R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, C1-C8 alkyl, C1-C6 alkoxy, nitro, cyano, acetoxy, amino, carboxy, sulfamyl, lower acylsulfamyl and trifluoromethyl. The compounds are inhibitors of cyclooxygenase-2 activity, useful for treating inflammation and cyclooxygenase-mediated disorders.

Abstract: The present invention relates to a process for preparing acylated 1,3-dicarbonyl compounds by rearrangement of corresponding enol esters. The invention also relates to the preparation of the corresponding tautomer compounds of the acylated 1,3-dicarbonyl compounds.

Abstract: Methods to recover nitramines from energetic materials yielding useable by-products and producing zero waste. The methods are used on materials containing HMX and RDX.

Abstract: A catalyst useful for oxidation reactions is disclosed. The catalyst is useful for the gas phase oxidation of alkanes, propylene, acrolein, or isopropanol to unsaturated aldehydes or carboxylic acids.

Abstract: In a process for preparing polyethylene waxes at from 200 to 350° C. and pressures in the range from 500 to 4 000 bar using molar mass regulators, a peroxide mixture comprising from 5 to 95% by weight of at least one cyclic peroxide of the formula I, where the radicals R are identical or different and are selected from among alkyl groups and aryl groups, is used as free radical initiator and a molar H2/ethylene ratio of from 1:2 000 to 1:40 000 is employed.

Abstract: Processes for producing citraconic anhydride and citraconic acid using porous materials with specific surface acidities and surface areas are described. The preferred catalyst is a porous gamma alumina. Itaconic acid is produced from citraconic acid. Itaconic acid is an intermediate to a variety of compounds including polymers.

Abstract: Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Abstract: The present invention provides a new and useful improvement in the process to manufacture a carboxylic acid salt, particularly an amino carboxylic acid salt, from a primary alcohol, particularly a primary aminoalcohol. The process of manufacturing amino carboxylic acid salts comprises contacting an aqueous solution of a primary aminoalcohol with a strong hydroxide base selected from the group consisting of an alkali metal hydroxide, an alkaline earth metal hydroxide, an ammonium hydroxide compound including a tetraalkyl ammonium hydroxide, or the like, in the presence of an effective amount of a catalyst. The catalyst comprises one or more of elements selected from the group consisting of copper, cobalt, nickel, and cadmium as well as optionally lesser amounts of chromium, titanium, niobium, tantalum, zirconium, vanadium, molybdenum, manganese, tungsten, cobalt, nickel, or mixtures thereof.

Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are of the following general formula, where X1, X2, Y, and Z are defined variables: Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.

Abstract: The present invention relates to methods, compositions, devices and kits for the prevention and treatment of prostate disorders in mammals, including, but not limited to, benign prostatic hypertrophy, carcinoma of the prostate, prostadynia, prostatitis, and chronic prostatitis. The present invention provides methods for preventing and treating prostate disorders in mammals by administration of a therapeutic compound to mucosal membranes in the lower urinary tract of the mammal. The present invention also provides devices for administering a therapeutic compound to mucosal membranes in the lower urinary tract of the mammal.

Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided Methods of administration and preparation are provided as well.

Abstract: The preferred embodiments provide for a family of novel compositions to serve as substrates that release hydroxy acid slowly over time. Preferably the hydroxy acid is an &agr;-hydroxy acid, more preferably it is lactic acid. The compositions are preferably made by reaction of poly(lactic acid) with multifunctional alcohols. Also disclosed are formulations based on the compounds and methods of use for both the compositions and the formulations. The preferred use of the compositions and formulations is for bioremediation purposes wherein they provide a time-release source of lactic acid to support the growth and reductive activity of microbes present in a system or medium, such as an aquifer, bioreactor, soil, industrial process, wastestream, body of water, river or well. The microbes destroy or inactivate compounds which are capable of being reduced, such as nitrogen-containing organic compounds, oxygen-containing organic compounds, polyaromatic hydrocarbons, and halogen-containing organic compounds.

Abstract: Compounds and pharmaceutical compositions useful as plasminogen activator inhibitor (PAI) antagonists are provided. In particular, methods of antagonizing PAI with substituted and unsubstituted aryl and heteroaryl ethers and thioethers are provided.

Abstract: A process for the synthesis and recovery of di(meth)acrylic acid esters at a high degree of purity. Di(meth)acrylic acid esters are produced by transesterfication of (meth)acrylic acid esters of C1 to C4 alcohols with 1,n-diols (where n≧3) in the presence of a zirconium catalyst that comprises a chelate of zirconium with a 1,3-dicarbonyl compound. These catalysts can be readily separated or removed from the reaction mixture by precipitation with phosphoric acid, thus providing a convenient and inexpensive method of producing a di(meth)acrylic acid ester with a reduced level of zirconium.

Abstract: This invention relates to an improved process for preparing acrylic acid from propylene using a tandem reactor and utilizing an increased amount of propylene reactant, thereby providing increased capacity and throughput. An improved process for purifying acrylic acid is also disclosed.